{
    "id": 749,
    "fullName": "EGFR over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EGFR over exp indicates an over expression of the Egfr protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "over exp",
    "createDate": "06/17/2014",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7849,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 2135,
                "therapyName": "TAK-285",
                "synonyms": null
            },
            "indication": {
                "id": 1749,
                "name": "squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1960,
                    "pubMedId": 23983820,
                    "title": "Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23983820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13058,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Theliatinib treatment resulted in significant tumor growth inhibition in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression (PMID: 28881608)",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 3668,
                "therapyName": "Theliatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8065,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3780,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 1749,
                "name": "squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8058,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1749,
                "name": "squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6934,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 demonstrated cytoxicity against a lung squamous cell carcinoma cell line with EGFR over expression in culture and induced tumor regression in EGFR over expressing lung squamous cell carcinoma cell line xenograft models (PMID: 26846818).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14473,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11643,
                    "pubMedId": 29533458,
                    "title": "Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533458"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17507,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with GC1118 resulted in an overall response rate of 8% (1/12; partial response), stable disease in 17% (2/12), and a median progression-free survival of 6.7 weeks in patients with EGFR-overexpressing gastric cancer (PMID: 31164456; NCT02352571).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 2913,
                "therapyName": "GC1118",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15519,
                    "pubMedId": 31164456,
                    "title": "A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31164456"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 670,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) treatment demonstrated a lack of benefit in the choriocarcinoma model of testicular germ cell tumor with high expression levels of EGFR, ERBB2 and ERBB3 (PMID: 23292912).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5557,
                "name": "testicular germ cell cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 389,
                    "pubMedId": 23292912,
                    "title": "ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23292912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 671,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) treatment demonstrated a complete lack of benefit in a cell line xenograft model of a choriocarcinoma testicular germ cell tumor expressing high levels of EGFR, ERBB2 and ERBB3 (PMID: 23292912).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5557,
                "name": "testicular germ cell cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 389,
                    "pubMedId": 23292912,
                    "title": "ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23292912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER sensitized both cetuximab-sensitive and cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) to radiation toxicity in culture and inhibited tumor growth in cell line xenograft models (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3886,
                "therapyName": "Pan-HER + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 669,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment resulted in 50% inhibition of tumor growth in a xenograft choriocarcinoma model of testicular germ cell tumor expressing high levels of EGFR, ERBB2 and ERBB3 (PMID: 23292912).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5557,
                "name": "testicular germ cell cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 389,
                    "pubMedId": 23292912,
                    "title": "ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23292912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5548,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER sensitized both cetuximab-sensitive and cetuximab-resistant non-small cell lung carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) to radiation toxicity in cell culture and inhibited tumor growth in patient-derived xenograft models (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3886,
                "therapyName": "Pan-HER + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8157,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited HER family receptors expression and signaling, suppressed growth of acquired and intrinsically cetuximab-resistant non-small cell lung carcinoma cell lines demonstrating high protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture and in cell line xenograft models (PMID: 27422810).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6563,
                    "pubMedId": 27422810,
                    "title": "Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5544,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited proliferation of both cetuximab-sensitive and cetuximab-resistant non-small cell lung carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8158,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited HER family receptors expression and signaling, suppressed growth of acquired and intrinsically cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture and in cell line xenograft models (PMID: 27422810).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6563,
                    "pubMedId": 27422810,
                    "title": "Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5545,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited proliferation of cetuximab-sensitive and cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 964,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",
            "molecularProfile": {
                "id": 23650,
                "profileName": "EGFR over exp ERBB2 dec exp"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 625,
                    "pubMedId": 24886365,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24886365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 965,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",
            "molecularProfile": {
                "id": 23650,
                "profileName": "EGFR over exp ERBB2 dec exp"
            },
            "therapy": {
                "id": 1416,
                "therapyName": "Paclitaxel + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 625,
                    "pubMedId": 24886365,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24886365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12224,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).",
            "molecularProfile": {
                "id": 26058,
                "profileName": "EGFR over exp FGFR1 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).",
            "molecularProfile": {
                "id": 26058,
                "profileName": "EGFR over exp FGFR1 amp"
            },
            "therapy": {
                "id": 4585,
                "therapyName": "AZD4547 + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).",
            "molecularProfile": {
                "id": 26059,
                "profileName": "EGFR over exp FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).",
            "molecularProfile": {
                "id": 26059,
                "profileName": "EGFR over exp FGFR2 amp"
            },
            "therapy": {
                "id": 4585,
                "therapyName": "AZD4547 + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8304,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, radiation induced over expression of EGFR and ERBB3 (HER3) in lung squamous cell carcinoma xenograft models demonstrated increased sensitivity when additionally treated with MEHD7945A, resulting in delayed tumor growth (PMID: 26141946).",
            "molecularProfile": {
                "id": 26227,
                "profileName": "EGFR over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 4683,
                "therapyName": "Duligotuzumab + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11662,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF G466A BRAF D594N EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 6103,
                "therapyName": "Capmatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11661,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF G466A BRAF D594N EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11660,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF G466A BRAF D594N EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28493,
                "profileName": "EGFR over exp KRAS wild-type"
            },
            "therapy": {
                "id": 6312,
                "therapyName": "Trametinib + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28493,
                "profileName": "EGFR over exp KRAS wild-type"
            },
            "therapy": {
                "id": 4482,
                "therapyName": "Afatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13059,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Theliatinib treatment resulted in tumor regression in patient-derived xenograft (PDX) models of esophageal cancer with both EGFR amplification and Egfr overexpression (PMID: 28881608)",
            "molecularProfile": {
                "id": 28988,
                "profileName": "EGFR amp EGFR over exp"
            },
            "therapy": {
                "id": 3668,
                "therapyName": "Theliatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13061,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression and PIK3CA E542K compared to models with only Egfr overexpression (PMID: 28881608).",
            "molecularProfile": {
                "id": 28989,
                "profileName": "EGFR over exp PIK3CA E542K"
            },
            "therapy": {
                "id": 3668,
                "therapyName": "Theliatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13060,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Theliatinib treatment demonstrated decreased efficacy in patient-derived xenograft (PDX) models of esophageal cancer with both Egfr and Fgfr1 overexpression compared to models with only Egfr overexpression (PMID: 28881608).",
            "molecularProfile": {
                "id": 28990,
                "profileName": "EGFR over exp FGFR1 over exp"
            },
            "therapy": {
                "id": 3668,
                "therapyName": "Theliatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13063,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 treatment resulted in tumor regression in patient-derived xenograft (PDX) models, with both Egfr and Fgfr1 overexpression (PMID: 28881608),",
            "molecularProfile": {
                "id": 28990,
                "profileName": "EGFR over exp FGFR1 over exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Egfr in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).",
            "molecularProfile": {
                "id": 31248,
                "profileName": "EGFR T790M EGFR L858R EGFR over exp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21137,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification demonstrated resistance to treatment with Capmatinib (INC280) and subsequently, were found to have increased expression of EGFR in culture (PMID: 30309221).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21131,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification and over expression of EGFR demonstrated sensitivity to the combination therapy of Piqray (alpelisib) and Capmatinib (INC280) in culture, resulting in decreased cell proliferation (PMID: 30309221).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 6313,
                "therapyName": "Afatinib + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18122,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHR-A1307 resulted in the inhibition of tumor growth in the EGFR overexpressing and MET amplified patient-derived xenograft models (PDX) of non-small cell lung cancer (PMID: 30962319).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1573,
            "profileName": "EGFR over exp ERBB2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2419,
            "profileName": "EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20975,
            "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23650,
            "profileName": "EGFR over exp ERBB2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25929,
            "profileName": "BRAF V600E EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26058,
            "profileName": "EGFR over exp FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26059,
            "profileName": "EGFR over exp FGFR2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26227,
            "profileName": "EGFR over exp ERBB3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28180,
            "profileName": "BRAF G466A BRAF D594N EGFR over exp MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28493,
            "profileName": "EGFR over exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28988,
            "profileName": "EGFR amp EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28989,
            "profileName": "EGFR over exp PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28990,
            "profileName": "EGFR over exp FGFR1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31248,
            "profileName": "EGFR T790M EGFR L858R EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32966,
            "profileName": "EGFR over exp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}